JNJ Stock Price Hits 28% Gain, But Analysts Warn of Premium Valuation
Johnson & Johnson (JNJ) has had an impressive year so far, with its stock price rising by 28% in total return. This outperforms both the S&P 500 ETF (SPY) and the Health Care Select Sector SPDR Fund (XLV), but despite this growth, the company's valuation is now considered premium.
The pharmaceutical giant delivered solid Q2 results and raised its FY 2026 guidance, but according to analysts, JNJ's stock price has become fully priced. This warrants a 'hold' rating from investors, who should be cautious of key risks including softness in MedTech growth, ongoing litigation, and macro uncertainties.
The company's technical performance is also showing signs of potential consolidation. Its Relative Strength Index (RSI) has entered negative divergence territory, and its valuation suggests that the stock may not continue to rise in the near term.